Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
- Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration
Basel, September23, 2020– Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this patient population and recommends a pivotal confirmatory study to supplement the existing STRONG data and further support the regulatory submission for AVXS-101 IT.
This guidance provides clarity on the path to registration for AVXS-101 IT. Trial design and other details are being evaluated and a comprehensive update on the overall Novartis SMA clinical development program will be provided at a future time following further discussions with health authorities. This request for a study is unrelated to the partial clinical hold on AVXS-101 IT, and the new study will not be initiated in the US until the hold has been lifted by the FDA. Novartis Gene Therapies remains confident in the overall benefit-risk profile for patients on treatment. This does not impact marketed Zolgensma®(onasemnogene abeparvovec) and the company continues to advance its regulatory filings and intravenous clinical studies.
Novartis Gene Therapies reaffirms its commitment to the SMA community and to pursuing solutions for patients with all types of SMA, including older children and adults. All patients deserve a gene therapy designed to address the genetic root cause of their disease with a single dose.
Zolgensma is approved in the US, Japan and, most recently, Brazil, for patients with SMA under the age of two. Zolgensma also continues to have a strong launch in Europe where it is approved for babies and young children with a clinical diagnosis of SMA Type 1 or SMA with up to three copies of the SMN2 gene, with dosing guidance provided up to 21 kg. More than 600 patients have benefited from Zolgensma, including through clinical trials, commercially and through the managed access program. This number is expected to continue to grow as this transformative gene therapy is approved in additional markets and as the company pursues additional studies to fully explore the impact of Zolgensma across a broad population of patients with SMA.
The company’s commitment to SMA extends beyond gene therapy to branaplam (LMI070), an oral, once-weekly RNA splicing modulator also currently under development, to expand the treatment options for SMA patients.
About Zolgensma® (onasemnogeneabeparvovec)
Zolgensma® is designed to address the genetic root cause of SMA by providing a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion. Zolgensma was approved by the US Food and Drug Administration in May 2019 and represents the first approved therapeutic in the company’s proprietary platform to treat rare, monogenic diseases using gene therapy. In addition to the US, Zolgensma is approved in Japan, Europe and Brazil. More than 600 patients have been treated with Zolgensma, including clinical trials, commercially and through the managed access program. Novartis Gene Therapies is pursuing registration in close to three dozen countries with regulatory decisions anticipated in Switzerland, Canada, Israel, Australia, and South Korea in late-2020 or early 2021.
About Spinal Muscular Atrophy
SMA is the leading genetic cause of infant death. If left untreated, SMA Type 1 leads to death or the need for permanent ventilation by the age of two in more than 90% of cases.
SMA is a rare, genetic neuromuscular disease caused by a lack of a functional SMN1 gene, resulting in the rapid and irreversible loss of motor neurons, affecting muscle functions, including breathing, swallowing and basic movement. It is imperative to diagnose SMA and begin treatment, including proactive supportive care, as early as possible to halt irreversible motor neuron loss and disease progression. This is especially critical in SMA Type 1, where motor neuron degeneration starts before birth and escalates quickly. Loss of motor neurons cannot be reversed, so SMA patients with symptoms at the time of treatment will likely require some supportive respiratory, nutritional and/or musculoskeletal care to maximize functional abilities. More than 30% of patients with SMA Type 2 will die by age 25.
About Novartis Gene Therapies
Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are turning promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). This therapy is now approved in the US, Japan, Europe and Brazil, and additional registrations are being pursued in close to three dozen countries, with regulatory decisions anticipated in Switzerland, Canada, Israel, Australia, Argentina and South Korea in late 2020 or early 2021. Our robust AAV-based pipeline is advancing treatments for Rett syndrome; a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene; and Friedreich’s ataxia. We are powered by the world’s largest gene therapy manufacturing footprint of more than one million square feet, enabling us to bring these therapies to patients around the world at quality and scale.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “to initiate,” “to evaluate,” “to further support,” “potential,” “recommends,” “to supplement,” “being evaluated,” “will,” “to advance,” “could,” “anticipated,” “remains,” “continues,” “to advance,” “reaffirms,” “commitment,” “to pursuing,” “to address,” “explore,” “investigational,” “launch,” “under development,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for AVXS-101 IT, Zolgensma and branaplam, or regarding potential future revenues from AVXS-101 IT, Zolgensma and branaplam. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that AVXS-101 IT or branaplam will be submitted or approved for sale in any market, or at any particular time. Neither can there be any guarantee that Zolgensma will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that AVXS-101 IT, Zolgensma or branaplam will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact firstname.lastname@example.org
# # #
Novartis Media Relations
|Anja von Treskow|
Novartis External Communications
+41 79 392 8697 (mobile)
Novartis US External Communications
+1 646 438 4335
|Farah Bulsara Speer|
SVP, Corporate Communications, Novartis Gene Therapies
+1 312 543 2881 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|Thomas Hungerbuehler |
|+41 61 324 8425|
+41 61 324 7188
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
RESULT OF RIKSBANK CERTIFICATE SALE1.12.2020 10:15:00 CET | Press release
RESULT OF RIKSBANK CERTIFICATE SALE CERTIFICATE MATURITY201209 FIXED RATE0.00 %OFFERED VOLUME380.000 BLNTOTAL BID AMOUNT1 526.300 BLNACCEPTED VOLUME 380.000 BLN PERCENTAGE ALLOTTED 24.8970 %NUMBER OF BIDS15DEPOSIT RATE-0.10 %LENDING RATE0.10 %
Net asset value as per November 30, 20201.12.2020 10:00:00 CET | Press release
On November 30, 2020, net asset value was SEK 278 per share. The closing price on November 30, 2020, was SEK 265.00 for the Class A shares and SEK 261.60 for the Class C shares. Stockholm, December 1, 2020 AB INDUSTRIVÄRDEN (publ) For further information, please contact: Sverker Sivall, Head of Corporate Communication and Sustainability, tel. +46-8-666 64 00 Submitted for publication on December 1, 2020 at 10:00 a.m. Attachment Substansvarde_201201_eng
Substansvärdet per den 30 november 20201.12.2020 10:00:00 CET | Pressemelding
Den 30 november 2020 var substansvärdet 278 kronor per aktie. Sista stängningskurs den 30 november 2020 var 265,00 kronor för A-aktien och 261,60 kronor för C-aktien. Stockholm den 1 december 2020 AB INDUSTRIVÄRDEN (publ) För ytterligare information kontakta: Sverker Sivall, Kommunikations- och hållbarhetschef, telefon 08-666 64 00 Lämnad för publicering den 1 december 2020, kl. 10:00. Bilaga Substansvarde_201201_sve
Exercise of warrants in Better Collective A/S; Board of Directors issues 111,086 new ordinary shares1.12.2020 08:45:00 CET | Press release
Regulatory Release 44/2020 In the exercise window which opened on November 11, 2020 following Better Collective’s Q3 report and closed on November 26, 2020, 22 employees have informed the company that they wish to exercise in total 111,086 warrants under the 2017 warrant program. The 2017 warrant program was established prior to the company’s IPO and the warrants were issued in 2017 and 2018. Reference is made to schedule 2 of the company’s articles of association for detailed terms of conditions of the warrants. As of November 11, 2020, 715,708 warrants remain outstanding (excluding the warrants exercised following the Q3 report) under the 2017 warrant program, all with rights to subscribe for 1 ordinary share in Better Collective A/S against payment of an exercise price of DKK 12.962962 per warrant. Today Better Collective’s board of directors resolved to carry out the capital increase related to the exercise of warrants. The new shares will be issued through VP Securities under the
Participation Notification by Blackrock Inc.1.12.2020 08:30:00 CET | Press release
Brussels, December 1, 2020, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notification indicating that it crossed the threshold of 3%. Here is a summary of the move: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalNovember 25, 20202.61%0.39%3.00% The latest notification, dated November 26, 2020, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: November 25, 2020Threshold of direct voting rights crossed: 3% upwardsDenominator: 105,876,416Additional information: The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3
Arcoma lanserar nya röntgensystemet OMNERA 500A på amerikanska marknaden1.12.2020 08:30:00 CET | Pressemelding
2020-12-01 PRESSRELEASE Arcoma lanserar nya röntgensystemet OMNERA 500A på amerikanska marknaden Arcoma AB lanserar idag det nya röntgensystemet OMNERA 500A på den amerikanska marknaden. OMNERA 500A erbjuder nya intelligenta automatiseringsfunktioner för att förbättra arbetsflödet och effektiviteten men även patientvården. OMNERA 500A erbjuder enastående prestanda och intelligent automatisering med funktioner som sätter effektivitet och patientsäkerhet främst. Systemet har ny design och ett nytt modernt användargränsnitt med smarta funktioner som förenklar arbetsflödet och är utformat för att underlätta desinficering. OMNERA 500A har också ett helt nytt väggstativ och ett uppdaterat röntgenbord som förbättrar patient- och användarupplevelsen. OMNERA 500A lanseras genom Arcomas partner Canon Medical Systems USA på den årliga mässan RSNA som i år utförs digitalt. Mässan pågår hela denna vecka. För att se det nya systemet i Canon Medical Systems digitala monter, besök deras hemsida: https